{"text": "rt AT_USER AT_USER adam please look into $bmy collaboration with AT_USER and $nwbo trial starts 4/17 URL"}
{"text": "$bmy bmo capital reiterates market perform rating, $45 pt URL"}
{"text": "bristol-myers squibb co $bmy rating reiterated by bmo capital markets URL"}
{"text": "bristol-myers squibb co $bmy rating reiterated by bmo capital markets URL"}
{"text": "rt AT_USER AT_USER adam please look into $bmy collaboration with AT_USER and $nwbo trial starts 4/17 URL"}
{"text": "rt AT_USER AT_USER adam please look into topline data dcvaxl p3 tba 2017 $nwbo recent $bmy #opdivo failure in gbm on time\u00a1\u00ad"}
{"text": "bristol-myers squibb co $bmy rating reiterated by bmo capital markets URL"}
{"text": "bristol-myers squibb co's market perform rating reiterated at bmo capital markets. $45.00 pt. URL $bmy #bmy"}
{"text": "bristol-myers squibb co's market perform rating reiterated at bmo capital markets. $45.00 pt. URL $bmy #bmy"}
{"text": "rt AT_USER AT_USER adam please look into topline data dcvaxl p3 tba 2017 $nwbo recent $bmy #opdivo failure in gbm on time\u00a1\u00ad"}
{"text": "rt AT_USER survival from checkmate-067 (opdivo+yervoy in melanoma), via james larkin $bmy #aacr17 URL"}
{"text": "rt AT_USER AT_USER AT_USER p3 topline gbm data tba #asco17 $bmy collaboration $nwbo and AT_USER #opdivo combo d\u00a1\u00ad"}
{"text": "rt AT_USER AT_USER AT_USER AT_USER #aacr17 #asco17 gbm timeline  #opdivo failure #glioblastoma $bmy now back st\u00a1\u00ad"}
{"text": "bristol-myers squibb co's market perform rating reiterated at bmo capital markets. $45.00 pt. URL $bmy #bmy"}
{"text": "rt AT_USER 5yr follow-up from ca209-003 study of opdivo in 2l nsclc, via julie brahmer $bmy #aacr17 URL"}
{"text": "$bmy possible long. - b: $54.36 / sl: $53.94 URL"}
{"text": "rt AT_USER survival from checkmate-067 (opdivo+yervoy in melanoma), via james larkin $bmy #aacr17 URL"}
{"text": "rt AT_USER 5yr follow-up from ca209-003 study of opdivo in 2l nsclc, via julie brahmer $bmy #aacr17 URL"}
{"text": "rt AT_USER AT_USER AT_USER #aacr17 looks like AT_USER $nwbo is our greatest hope gbm $bmy opdivo failed ht\u00a1\u00ad"}
{"text": "rt AT_USER AT_USER are you aware that $nwbo and $bmy are starting a trial to compare dcvax-l v dcvax-l+nivolumab? isn't it clear what\u00a1\u00ad"}
{"text": "rt AT_USER 5yr follow-up from ca209-003 study of opdivo in 2l nsclc, via julie brahmer $bmy #aacr17 URL"}
{"text": "rt AT_USER $bmy  - #fail - announces results from checkmate -143, a phase 3 study of opdivo (nivolumab) in patients with glioblastoma mu\u00a1\u00ad"}
{"text": "AT_USER adam please look into topline data dcvaxl p3 tba 2017 $nwbo recent $bmy #opdivo failure in gbm on t\u00a1\u00ad URL"}
{"text": "rt AT_USER AT_USER adam please look into $bmy collaboration with AT_USER and $nwbo trial starts 4/17 URL"}
{"text": "AT_USER adam please look into $bmy collaboration with AT_USER and $nwbo trial starts 4/17 URL"}
{"text": "need help finding momentum stocks? URL URL $htgm $jah $clr $dis $mo $bmy $pot $apa $cnq $ccl"}
{"text": "newlink slipstreams behind incyte URL $mrk $rhhby $bmy $nlnk $incy"}
{"text": "rt AT_USER AT_USER are you aware that $nwbo and $bmy are starting a trial to compare dcvax-l v dcvax-l+nivolumab? isn't it clear what\u00a1\u00ad"}
{"text": "$bmy: bristol-myers: fda accepts sbla that seeks to extend the use of opdivo to patients with mismatch repair... URL"}
{"text": "rt AT_USER AT_USER AT_USER p3 topline gbm data tba #asco17 $bmy collaboration $nwbo and AT_USER #opdivo combo d\u00a1\u00ad"}
{"text": "rt AT_USER AT_USER AT_USER #aacr17 looks like AT_USER $nwbo is our greatest hope gbm $bmy opdivo failed ht\u00a1\u00ad"}
{"text": "rt AT_USER AT_USER are you aware that $nwbo and $bmy are starting a trial to compare dcvax-l v dcvax-l+nivolumab? isn't it clear what\u00a1\u00ad"}
{"text": "rt AT_USER $bmy reveal first overall survival data readout from checkmate-067 study of opdivo and yervoy URL #a\u00a1\u00ad"}
{"text": "rt AT_USER AT_USER are you aware that $nwbo and $bmy are starting a trial to compare dcvax-l v dcvax-l+nivolumab? isn't it clear what\u00a1\u00ad"}
{"text": "rt AT_USER $bmy s\u00a1\u00af checkpoint star opdivo fails a phiii study for #glioblastoma URL #gbm #aacr17"}
{"text": "rt AT_USER 5yr follow-up from ca209-003 study of opdivo in 2l nsclc, via julie brahmer $bmy #aacr17 URL"}
{"text": "rt AT_USER 5yr follow-up from ca209-003 study of opdivo in 2l nsclc, via julie brahmer $bmy #aacr17 URL"}
{"text": "#bristolmyerssquibb bristol-myers announces data on immuno-oncology drug opdivo . read more: URL $bmy"}
{"text": "#bristolmyerssquibb bristol-myers announces data on immuno-oncology drug opdivo . read more: URL $bmy"}
{"text": "rt AT_USER $bmy reveal first overall survival data readout from checkmate-067 study of opdivo and yervoy URL #a\u00a1\u00ad"}
{"text": "rt AT_USER AT_USER AT_USER AT_USER #aacr17 #asco17 gbm timeline  #opdivo failure #glioblastoma $bmy now back st\u00a1\u00ad"}
{"text": "rt AT_USER AT_USER AT_USER #aacr17 looks like AT_USER $nwbo is our greatest hope gbm $bmy opdivo failed ht\u00a1\u00ad"}
{"text": "rt AT_USER AT_USER AT_USER p3 topline gbm data tba #asco17 $bmy collaboration $nwbo and AT_USER #opdivo combo d\u00a1\u00ad"}
{"text": "rt AT_USER AT_USER AT_USER AT_USER #aacr17 #asco17 gbm timeline  #opdivo failure #glioblastoma $bmy now back st\u00a1\u00ad"}
{"text": "AT_USER AT_USER AT_USER can only go by data presented in these situation. hopefully to see more data\u00a1\u00ad URL"}
{"text": "AT_USER AT_USER AT_USER #aacr17 #asco17 gbm timeline  #opdivo failure #glioblastoma $bmy now back\u00a1\u00ad URL"}
{"text": "rt AT_USER 5yr follow-up from ca209-003 study of opdivo in 2l nsclc, via julie brahmer $bmy #aacr17 URL"}
{"text": "AT_USER AT_USER p3 topline gbm data tba #asco17 $bmy collaboration $nwbo and AT_USER #opdivo comb\u00a1\u00ad URL"}
{"text": "bristol-myers squibb co $bmy receives consensus recommendation of \u00a1\u00b0hold\u00a1\u00b1 from brokerages URL"}
{"text": "$bmy reveal first overall survival data readout from checkmate-067 study of opdivo and yervoy URL #aacr17"}
{"text": "$bmy ido1 first peek (must've had mrk on the brain i said mrk initially) URL"}
{"text": "bristol-myers squibb co $bmy receives consensus recommendation of \u00a1\u00b0hold\u00a1\u00b1 from brokerages URL #acn"}
{"text": "$bmy fda accepts sbla that seeks to extend the use of opdivo to patients with mismatch repair deficient or microsa\u00a1\u00ad URL"}
{"text": "bristol-myers squibb co $bmy receives consensus recommendation of \u00a1\u00b0hold\u00a1\u00b1 from brokerages URL"}
{"text": "fda has assigned a decision date of 8/2 for $bmy\u00a1\u00afs opdivo marketing application for dmmr or msi-h metastatic crc.\u00a1\u00ad URL"}
{"text": "$bmy *fda accepts priority review of bristol-myers sbla application"}
{"text": "$bmy *bristol-myers: priority review for sbla to extend use of opdivo"}
{"text": "AT_USER AT_USER roche decision wrt epac the most interesting one imo. can argue $mrk / $bmy acting defensively, but roche unlikely to"}
{"text": "$bmy playing it conservatively on booth size this year, the effects of not stratifying pd-l1 in nsclc in one pictur\u00a1\u00ad URL"}
{"text": "rt AT_USER survival from checkmate-067 (opdivo+yervoy in melanoma), via james larkin $bmy #aacr17 URL"}
{"text": "rt AT_USER good morning #aacr17 everyone ready for ido day? $incy $bmy URL $nlnk URL"}
{"text": "rt AT_USER 5yr follow-up from ca209-003 study of opdivo in 2l nsclc, via julie brahmer $bmy #aacr17 URL"}
{"text": "newlink slipstreams behind incyte URL $mrk $rhhby $bmy $nlnk $incy"}
{"text": "newlink slipstreams behind incyte URL $mrk $rhhby $bmy $nlnk $incy"}
{"text": "newlink slipstreams behind incyte URL $mrk $rhhby $bmy $nlnk $incy"}
{"text": "#bristolmyerssquibb bms opdivo shown to improve fiveyear lung cancer survival. read more: URL $bmy"}
{"text": "#bristolmyerssquibb bms' opdivo shown to improve five-year lung cancer survival. read more: URL $bmy"}
{"text": "#bristolmyerssquibb bms' opdivo shown to improve five-year lung cancer survival. read more: URL $bmy"}
{"text": "#bristolmyerssquibb bms opdivo shown to improve fiveyear lung cancer survival. read more: URL $bmy"}
{"text": "AT_USER when should i add more $bmy"}
{"text": "$bmy a close at these levels takes me out. stop just below break even, will take small loss"}
{"text": "$bmy s\u00a1\u00af checkpoint star opdivo fails a phiii study for #glioblastoma URL #gbm #aacr17"}
{"text": "rt AT_USER today's $nlnk #aacr17 data, and the broader ido timeline #asco17 #esmo17 via AT_USER URL $incy $mrk\u00a1\u00ad"}
{"text": "oncbiomune to become a revenue-generating international pharmaceutical company URL $nvs $pfe $ibb $gild $jnj $bmy $mrk"}
{"text": "rt AT_USER today's $nlnk #aacr17 data, and the broader ido timeline #asco17 #esmo17 via AT_USER URL $incy $mrk\u00a1\u00ad"}
{"text": "biotech investors : URL $ibb $nvs $pfe $gild $mrk $bmy $amgn $orex $incy"}
{"text": "rt AT_USER $repcf $rp.v &amp; few other #biomedical stocks to watch today... $gnmx $usrm $pfe $bmy $sgyp $auph $vrx $myl $biib"}
{"text": "#bristolmyerssquibb bristol-myers squibb co to issue quarterly dividend of $0.39 on  may 1st. read more: URL $bmy"}
{"text": "#bristolmyerssquibb bristol-myers (), incyte to advance clinical program - april 3, 2017. read more: URL $bmy"}
{"text": "#bristolmyerssquibb bristol-myers squibb co to issue quarterly dividend of $0.39 on  may 1st. read more: URL $bmy"}
{"text": "$bmy .+nailed it URL"}
{"text": "#bristolmyerssquibb bristol-myers (), incyte to advance clinical program - april 3, 2017. read more: URL $bmy"}
{"text": "#bristolmyerssquibb bristol-myers (), incyte to advance clinical program. read more: URL $bmy"}
{"text": "#bristolmyerssquibb bristol-myers (), incyte to advance clinical program. read more: URL $bmy"}
{"text": "#bristolmyerssquibb bristol-myers squibb's next big bet after opdivo failure-idos  . read more: URL $bmy"}
{"text": "#bristolmyerssquibb bristol-myers squibb's next big bet after opdivo failure-idos  . read more: URL $bmy"}
{"text": "rt AT_USER today's $nlnk #aacr17 data, and the broader ido timeline #asco17 #esmo17 via AT_USER URL $incy $mrk\u00a1\u00ad"}
{"text": "$bmy presents new data evincing opdivo's long-term benefits URL #aacr17"}
{"text": "$bmy presents new data evincing opdivo's long-term benefits URL #aacr17"}
{"text": "rt AT_USER today's $nlnk #aacr17 data, and the broader ido timeline #asco17 #esmo17 via AT_USER URL $incy $mrk\u00a1\u00ad"}
{"text": "rt AT_USER today's $nlnk #aacr17 data, and the broader ido timeline #asco17 #esmo17 via AT_USER URL $incy $mrk\u00a1\u00ad"}
{"text": "rt AT_USER key #aacr17 presentation. postmortem of checkmate-026 $bmy $mrk $rhhby $azn $pfe URL"}
{"text": "rt AT_USER today's $nlnk #aacr17 data, and the broader ido timeline #asco17 #esmo17 via AT_USER URL $incy $mrk\u00a1\u00ad"}
{"text": "rt AT_USER today's $nlnk #aacr17 data, and the broader ido timeline #asco17 #esmo17 via AT_USER URL $incy $mrk\u00a1\u00ad"}
{"text": "rt AT_USER today's $nlnk #aacr17 data, and the broader ido timeline #asco17 #esmo17 via AT_USER URL $incy $mrk\u00a1\u00ad"}
{"text": "vantage snippet - no checkmate this time as opdivo comes up short in brain cancer $bmy URL"}
{"text": "rt AT_USER today's $nlnk #aacr17 data, and the broader ido timeline #asco17 #esmo17 via AT_USER URL $incy $mrk\u00a1\u00ad"}
{"text": "today's $nlnk #aacr17 data, and the broader ido timeline #asco17 #esmo17 via AT_USER URL $incy $mrk $rhhby $bmy"}
{"text": "$obmp oncbiomune to become a revenue-generating international pharmaceutical company URL $ibb $nvs $pfe $jnj $mrk $bmy"}
{"text": "#bristolmyerssquibb bristol-myers squibb and incyte to advance the combination of opdivo (ni... read more: URL $bmy"}
